Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

Abstract Background Diabetes mellitus type 2 (DM2) is a risk factor for developing heart failure but there is no specific therapy for diabetic heart disease. Sodium glucose transporter 2 inhibitors (SGLT2I) are recently developed diabetic drugs that primarily work on the kidney. Clinical data descri...

Full description

Bibliographic Details
Main Authors:	M. Arow, M. Waldman, D. Yadin, V. Nudelman, A. Shainberg, N. G. Abraham, D. Freimark, R. Kornowski, D. Aravot, E. Hochhauser, M. Arad
Format:	Article
Language:	English
Published:	BMC 2020-01-01
Series:	Cardiovascular Diabetology
Subjects:	Diabetes mellitus type 2 Cardiomyopathy Dapagliflozin Cardiomyocytes Calcium transport fibrosis Inflammation
Online Access:	https://doi.org/10.1186/s12933-019-0980-4

Similar Items

Exercise Augments the Effect of SGLT2 Inhibitor Dapagliflozin on Experimentally Induced Diabetic Cardiomyopathy, Possible Underlying Mechanisms
by: Mamdouh Eldesoqui, et al.
Published: (2022-07-01)

Dapagliflozin Protects Methamphetamine-Induced Cardiomyopathy by Alleviating Mitochondrial Damage and Reducing Cardiac Function Decline in a Mouse Model
by: Shanqing He, et al.
Published: (2022-07-01)

SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin
by: Stephan Dobner, et al.
Published: (2023-02-01)

Integrated Omics Insights into Dapagliflozin Effects in Sepsis-Induced Cardiomyopathy
by: Weiwei Lai, et al.
Published: (2025-02-01)

Quantitative effects of sodium–glucose cotransporter-2 inhibitors dapagliflozin and empagliflozin on quality of life in heart failure patients
by: Dong-Dong Wang, et al.
Published: (2022-11-01)

Therapeutic effects on the development of heart failure with preserved ejection fraction by the sodium-glucose cotransporter 2 inhibitor dapagliflozin in type 2 diabetes
by: Bin Feng, et al.
Published: (2023-06-01)

Effect of the Sodium-Glucose Cotransporter 2 Inhibitor, Dapagliflozin, on Genitourinary Infection in an Animal Model of Type 2 Diabetes
by: Jin Bong Choi, et al.
Published: (2020-03-01)

Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin–metformin
by: Schwartz SS, et al.
Published: (2016-03-01)

Appropriate Dose of Dapagliflozin Improves Cardiac Outcomes by Normalizing Mitochondrial Fission and Reducing Cardiomyocyte Apoptosis After Acute Myocardial Infarction
by: Fan ZG, et al.
Published: (2022-06-01)

Regulation of diabetic cardiomyopathy by caloric restriction is mediated by intracellular signaling pathways involving ‘SIRT1 and PGC-1α’
by: Maayan Waldman, et al.
Published: (2018-08-01)

Inhibition of Sodium-GlucoseCotransporter 2 with Dapagliflozin in Han: SPRD Rats with Polycystic Kidney Disease
by: Daniel Rodriguez, et al.
Published: (2015-12-01)

Comparative Study of the Efficacy and Safety of Sacubitril/Valsartan and Dapagliflozin in the Treatment of Dilated Cardiomyopathy with Low Blood Pressure
by: ZHANG Yong, CAI Xiang, NING Feifei, LIANG Xiao, GUO Ning
Published: (2023-08-01)

Role of Dapagliflozin and Liraglutide on Diabetes-Induced Cardiomyopathy in Rats: Implication of Oxidative Stress, Inflammation, and Apoptosis
by: Mohamed El-Shafey, et al.
Published: (2022-03-01)

Dapagliflozin mitigates cellular stress and inflammation through PI3K/AKT pathway modulation in cardiomyocytes, aortic endothelial cells, and stem cell-derived β cells
by: Fatmah R. Alsereidi, et al.
Published: (2024-10-01)

Empagliflozin and Dapagliflozin Increase Na<sup>+</sup> and Inward Rectifier K<sup>+</sup> Current Densities in Human Cardiomyocytes Derived from Induced Pluripotent Stem Cells (hiPSC-CMs)
by: María Dago, et al.
Published: (2022-11-01)

A SGLT2 Inhibitor Dapagliflozin Alleviates Diabetic Cardiomyopathy by Suppressing High Glucose-Induced Oxidative Stress in vivo and in vitro
by: Yu-jie Xing, et al.
Published: (2021-07-01)

Stratified Treatment of Heart Failure with preserved Ejection Fraction: rationale and design of the STADIA‐HFpEF trial
by: Mariëlle Scheffer, et al.
Published: (2020-12-01)

Sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents ejection fraction reduction, reduces myocardial and renal NF-κB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity
by: V. Quagliariello, et al.
Published: (2024-05-01)

EVALUATION OF THE MACROMOLECULAR STRUCTURE OF CARDIAC MYOCYTES IN PATIENTS WITH VARIOUS FORMS OF CARDIOMYOPATHY
by: A. G. Kupriyanova, et al.
Published: (2012-05-01)

A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects
by: Kim HC, et al.
Published: (2023-04-01)

Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1)
by: A. A. Avagimyan, et al.
Published: (2024-11-01)

Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 2)
by: Ashot A. Avagimyan, et al.
Published: (2025-02-01)

Altered Metabolic Phenotypes and Hypothalamic Neuronal Activity Triggered by Sodium-Glucose Cotransporter 2 Inhibition
by: Ho Gyun Lee, et al.
Published: (2023-11-01)

Sodium–glucose cotransporter‐2 inhibitors induced euglycemic diabetic ketoacidosis: Two case reports and a review of the literature
by: Zouheir Ibrahim Bitar, et al.
Published: (2022-02-01)

Dapagliflozin: a sodium–glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling
by: Yuze Zhang, et al.
Published: (2021-06-01)

Comparison of Cardioprotective Effects of Dapagliflozin and Trimetazidine in the Model of Doxorubicin-Cyclophosphamide Cardiotoxicity
by: A. A. Avagimyan, et al.
Published: (2023-11-01)

Dapagliflozin attenuates hypoxia/reoxygenation-caused cardiac dysfunction and oxidative damage through modulation of AMPK
by: Kun-Ling Tsai, et al.
Published: (2021-02-01)

Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension
by: Yi Tang, et al.
Published: (2022-04-01)

Sodium-glucose cotransporter-2 inhibition and the insulin: Glucagon ratio: Unexplored dimensions
by: Sanjay Kalra, et al.
Published: (2015-01-01)

Cardiomyopathies and Arrhythmias Induced by Cancer Therapies
by: Dragoș-Mihai Romitan, et al.
Published: (2020-11-01)

Repurposing dapagliflozin for Alzheimer's disease: a mechanistic exploration
by: Marwa M. Saeed
Published: (2024-12-01)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
by: Santos Cavaiola T, et al.
Published: (2018-04-01)

Pathogenetic Role of the Mitral Valve at Hypertrophic Cardiomyopathy
by: V. P. Zakharova, et al.
Published: (2019-12-01)

Dapagliflozin Ameliorates Neural Damage in the Heart and Kidney of Diabetic Mice
by: Ionuț Donoiu, et al.
Published: (2023-12-01)

Practice of Dapagliflozin Application in Patients with Type 2 Diabetes Mellitus
by: L.V. Shkala, et al.
Published: (2015-08-01)

ADDition of DAPAgliflozin, Sodium-Glucose Cotransporter-2 Inhibitor to Angiotensin Receptor Blocker-Neprilysin Inhibitors Non-Responders in Patient with Refractory Heart Failure with Reduced Ejection Fraction (ADD DAPA trial)
by: Pankaj Jariwala, MD, DNB, DNB, MNAMS, FACC, FSCAI, et al.
Published: (2021-09-01)

Dapagliflozin's effect on serum homocysteine in patients with hypertension complicated with insulin resistance
by: Xiaoqian Yu, et al.
Published: (2023-05-01)

The The Impact of Dapagliflozin on Aldosterone Hormone in Rats with Heart Failure
by: Skala Mamand Jawhar, et al.
Published: (2023-09-01)

Safety, tolerability, and effectiveness of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in combination with standard chemotherapy for patients with advanced, inoperable pancreatic adenocarcinoma: a phase 1b observational study
by: Lauren K. Park, et al.
Published: (2023-05-01)

Exenatide and Dapagliflozin Combination Enhances Sertoli Cell Secretion of Key Metabolites for Spermatogenesis
by: João C. Ribeiro, et al.
Published: (2022-05-01)